Figure 2: PCSK9 Reduces LDLR Expression in Human Primary Hepatocytes: An Effect Blocked by Alirocumab
2019-06-11T07:03:07Z (GMT) by
Low-density lipoprotein receptor (LDLR) expression was measured in hepatocytes, treated for 72 h with increasing concentrations of recombinant PCSK9 with or without saturating concentrations (8 μg/ml) of alirocumab, by simple western blot. LDLR levels were normalized to transferrin receptor expression. Histograms represent the mean ± SEM of 3 independent experiments. *p < 0.01 vs. control (no PCSK9); **p < 0.05 vs. same dose of PCSK9 without alirocumab, using 1-way analysis of variance on rank-transformed values with post-hoc Newman-Keuls test. A representative simple Western image is displayed. Abbreviations as in Figure 1.